About Abcam
Abcam is a company based in Cambridge (United Kingdom) founded in 1998 by Avner Dahan and Tony Kouzarides was acquired by Danaher in August 2023. Abcam has raised $78.8 million across 6 funding rounds from investors including Danaher, HHS and National Science Foundation. Abcam has completed 12 acquisitions, including Ascent Scientific, AxioMx and BioVision. Abcam offers products and services including Primary Antibodies, ELISA Kits, and Cell Lines. Abcam operates in a competitive market with competitors including Stem Cell Technologies, Meridian Bioscience, Teknova, Sangon Biotech and Cayman Chem, among others.
- Headquarter Cambridge, United Kingdom
- Founders Avner Dahan, Tony Kouzarides
- Stage Public
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Abcam Limited
- Date of Incorporation 12 Feb, 1998
- Jurisdiction CAMBRIDGE, UNITED KINGDOM
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$78.8 M (USD)
in 6 rounds
-
Latest Funding Round
$258.66 M (USD), Debt – Conventional
May 15, 2019
-
Investors
Danaher
& 2 more
-
Employee Count
Not available
-
Investments & Acquisitions
Ascent Scientific
& 11 more
-
Acquired by
Danaher
(Aug 26, 2023)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Abcam
Abcam offers a comprehensive portfolio of products and services, including Primary Antibodies, ELISA Kits, and Cell Lines.
Antibodies for detecting specific proteins in biological samples
Kits for measuring proteins and analytes in research assays
Gene-edited cells for experimental and therapeutic studies
People of Abcam
Unlock access to complete
Unlock access to complete
Sales and Marketing
18 people
Software Development Team
17 people
Senior Team
15 people
Product Management Team
9 people
Leadership Team
5 people
Finance and Accounting
5 people
Human Resources and Administration
5 people
Head Team
4 people
Unlock access to complete
Funding Insights of Abcam
Abcam has successfully raised a total of $78.8M across 6 strategic funding rounds. The most recent funding activity was a Debt – Conventional round of $258.66 million completed in May 2019. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Abcam
Abcam has secured backing from 3 investors, including institutional investors. Prominent investors backing the company include Danaher, HHS and National Science Foundation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Public health and human services are overseen by HHS.
|
Locked | Locked | Locked | |
|
A government-backed foundation providing seed-stage investments to support small businesses.
|
Locked | Locked | Locked | |
|
Dental equipment and medical instruments are manufactured for therapeutic areas.
|
Locked | Locked | Locked |
Investor details for Abcam
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Abcam
Abcam has strategically engaged in corporate development activities, having acquired 12 companies. Notable acquisitions include Ascent Scientific, AxioMx and BioVision.
Investment portfolio details for Abcam
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Age-related disorders are addressed through senescent biology research.
|
Locked | Locked | 2013 | Locked | |
|
A recombinant antibody discovery and development platform is operated.
|
Locked | Locked | 2012 | Locked | |
|
Custom rabbit monoclonal antibodies are developed for research applications.
|
Locked | Locked | 2012 | Locked |
Complete acquisition details for Abcam
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Abcam
Detailed financials for Abcam
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Abcam Comparisons
Peer comparison for Abcam
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Abcam
Abcam operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Stem Cell Technologies, Meridian Bioscience, Teknova, Sangon Biotech and Cayman Chem, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Developer of cell culture media and ancillary reagents for life science research
|
|
| Locked | Locked | Locked |
Molecular diagnostic device and kits
|
|
| Locked | Locked | Locked |
Molecular biology reagents and kits are supplied for research applications.
|
|
| Locked | Locked | Locked |
Research services, reagents, and kits for biotech applications are provided.
|
|
| Locked | Locked | Locked |
Bioreagents and assay kits are developed, with preclinical services provided.
|
Detailed competitors of Abcam
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Abcam
Complete news archive for Abcam
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Abcam
Abcam was founded in 1998 and raised its 1st funding round 11 years after it was founded.
Abcam is headquartered in Cambridge, United Kingdom. It is registered at Cambridge, Cambridgeshire, United Kingdom.
Abcam is a funded company, having raised a total of $78.8M across 6 funding rounds to date.
Abcam was founded in 1998 in Cambridge, United Kingdom, within the life sciences sector. Biological reagents are produced for research applications, encompassing primary and secondary antibodies, immunoassay kits, cellular imaging tools, biochemical assays, proteins, peptides, proteomic tools, agonists, antagonists, activators, inhibitors, lysates, and miRNA assays. Operations focus on supporting scientific investigations through these specialized products.
Abcam's top competitors include Meridian Bioscience, Stem Cell Technologies and BBI Solutions.
Abcam offers Primary Antibodies, ELISA Kits, and Cell Lines.
Abcam has made 12 acquisitions, including Ascent Scientific, AxioMx, and BioVision.
Abcam has 3 investors. Key investors include Danaher, HHS, and National Science Foundation.